Roche contends with loss of momentum for key medicines, currency fluctuations in Q3 but keeps growth on track
23rd October 2025 Uncategorised 0Even as Roche executives on Wednesday espoused confidence in the company’s resilience and growth potential over the next several years, a mix of exchange rate fluctuations and lackluster pharmaceutical sales led to a worse-than-expected third quarter for the Swiss drug giant.
More: Roche contends with loss of momentum for key medicines, currency fluctuations in Q3 but keeps growth on track
Source: fierce
